{"id":925743,"date":"2026-01-08T20:33:33","date_gmt":"2026-01-09T01:33:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/"},"modified":"2026-01-08T20:33:33","modified_gmt":"2026-01-09T01:33:33","slug":"investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/","title":{"rendered":"INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\">NEWTOWN, Pa.<\/span>, <span class=\"legendSpanClass\">Jan. 8, 2026<\/span> \/PRNewswire\/ &#8212; <b>Edelson\u00a0Lechtzin LLP<\/b>\u00a0is investigating potential violations of the federal securities laws involving Ventyx Biosciences, Inc. (&#8220;Ventyx&#8221;) (NASDAQ: VTYX), resulting from allegations of providing potentially misleading business information to the investing public.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2457789\/logo2_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2457789\/logo2_Logo.jpg\" title=\"Edelson Lechtzin LLP (PRNewsfoto\/Edelson Lechtzin LLP)\" alt=\"Edelson Lechtzin LLP (PRNewsfoto\/Edelson Lechtzin LLP)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b>If you have information that could assist in the Ventyx Investigation or if you are a Ventyx investor who suffered a loss and would like to learn more, you can provide your information <\/b><br \/>\n        <b><br \/>\n          <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4592421-1&amp;h=2153489752&amp;u=https%3A%2F%2Fedelsonlechtzin.cliogrow.com%2Fintake%2F038EKHUraenVUPTAnnoXEQ&amp;a=HERE\" target=\"_blank\" rel=\"nofollow\">HERE<\/a><br \/>\n        <\/b><br \/>\n        <b>.<\/b>\n      <\/p>\n<p>You can also contact attorney Eric Lechtzin by calling 844-563-5550, ext. 1, or via email at <a href=\"mailto:elechtzin@edelson-law.com\" target=\"_blank\" rel=\"nofollow\">elechtzin@edelson-law.com<\/a>.<\/p>\n<p>\n        <b>THE COMPANY: <\/b>\n      <\/p>\n<p>Ventyx Biosciences develops oral therapies for autoimmune, inflammatory, and neurodegenerative diseases.<\/p>\n<p>\n        <b>THE <span>ALLEGED<\/span> WRONGDOING:<\/b>\n      <\/p>\n<p>On December 2, 2025, Ventyx updated its Phase 2 trial of VTX2735 for recurrent pericarditis, announcing that topline results are now expected in Q1 2026. The CEO explained that the delay will allow the company to test a new once-daily formulation and expand the study into Canada, the EU, and the UK to accelerate Phase 3 development. On this news, Ventyx&#8217;s stock price fell $1.44 per share, or 15.35%, to close at $7.94 per share on December 2, 2025.<\/p>\n<p>\n        <b>ABOUT EDELSON LECHTZIN LLP: <\/b>Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to cases involving securities and investment <span>fraud<\/span>, our lawyers focus on class and collective litigation alleging violations of the federal antitrust laws, ERISA employee benefit plans, wage theft and unpaid overtime, consumer <span>fraud<\/span>, and dangerous and defective drugs and medical devices.<\/p>\n<p>\n        <b><br \/>\n          <u>For more information, please contact:<\/u><br \/>\n        <\/b>\n      <\/p>\n<p>Eric Lechtzin, Esq.<br \/>EDELSON LECHTZIN LLP<br \/>411 S. State Street, Suite N-300<br \/>Newtown, PA 18940<br \/>Phone: 844-696-7492 ext. 1<br \/>Email: <a href=\"mailto:elechtzin@edelson-law.com\" target=\"_blank\" rel=\"nofollow\">elechtzin@edelson-law.com<\/a><br \/>Web:\u00a0 <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4592421-1&amp;h=1624585901&amp;u=http%3A%2F%2Fwww.edelson-law.com%2F&amp;a=www.edelson-law.com\" target=\"_blank\" rel=\"nofollow\">www.edelson-law.com<\/a>\u00a0<\/p>\n<p>This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. Your ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=PH59781&amp;sd=2026-01-08\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information-to-contact-the-firm-302656991.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information-to-contact-the-firm-302656991.html<\/a><\/p>\n<p>SOURCE Edelson Lechtzin LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PH59781&amp;Transmission_Id=202601082030PR_NEWS_USPR_____PH59781&amp;DateId=20260108\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEWTOWN, Pa., Jan. 8, 2026 \/PRNewswire\/ &#8212; Edelson\u00a0Lechtzin LLP\u00a0is investigating potential violations of the federal securities laws involving Ventyx Biosciences, Inc. (&#8220;Ventyx&#8221;) (NASDAQ: VTYX), resulting from allegations of providing potentially misleading business information to the investing public. If you have information that could assist in the Ventyx Investigation or if you are a Ventyx investor who suffered a loss and would like to learn more, you can provide your information HERE . You can also contact attorney Eric Lechtzin by calling 844-563-5550, ext. 1, or via email at elechtzin@edelson-law.com. THE COMPANY: Ventyx Biosciences develops oral therapies for autoimmune, inflammatory, and neurodegenerative diseases. THE ALLEGED WRONGDOING: On December 2, 2025, Ventyx updated its Phase 2 trial of VTX2735 for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-925743","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEWTOWN, Pa., Jan. 8, 2026 \/PRNewswire\/ &#8212; Edelson\u00a0Lechtzin LLP\u00a0is investigating potential violations of the federal securities laws involving Ventyx Biosciences, Inc. (&#8220;Ventyx&#8221;) (NASDAQ: VTYX), resulting from allegations of providing potentially misleading business information to the investing public. If you have information that could assist in the Ventyx Investigation or if you are a Ventyx investor who suffered a loss and would like to learn more, you can provide your information HERE . You can also contact attorney Eric Lechtzin by calling 844-563-5550, ext. 1, or via email at elechtzin@edelson-law.com. THE COMPANY: Ventyx Biosciences develops oral therapies for autoimmune, inflammatory, and neurodegenerative diseases. THE ALLEGED WRONGDOING: On December 2, 2025, Ventyx updated its Phase 2 trial of VTX2735 for &hellip; Continue reading &quot;INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-09T01:33:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2457789\/logo2_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm\",\"datePublished\":\"2026-01-09T01:33:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\\\/\"},\"wordCount\":384,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2457789\\\/logo2_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\\\/\",\"name\":\"INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2457789\\\/logo2_Logo.jpg\",\"datePublished\":\"2026-01-09T01:33:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2457789\\\/logo2_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2457789\\\/logo2_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/","og_locale":"en_US","og_type":"article","og_title":"INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm - Market Newsdesk","og_description":"PR Newswire NEWTOWN, Pa., Jan. 8, 2026 \/PRNewswire\/ &#8212; Edelson\u00a0Lechtzin LLP\u00a0is investigating potential violations of the federal securities laws involving Ventyx Biosciences, Inc. (&#8220;Ventyx&#8221;) (NASDAQ: VTYX), resulting from allegations of providing potentially misleading business information to the investing public. If you have information that could assist in the Ventyx Investigation or if you are a Ventyx investor who suffered a loss and would like to learn more, you can provide your information HERE . You can also contact attorney Eric Lechtzin by calling 844-563-5550, ext. 1, or via email at elechtzin@edelson-law.com. THE COMPANY: Ventyx Biosciences develops oral therapies for autoimmune, inflammatory, and neurodegenerative diseases. THE ALLEGED WRONGDOING: On December 2, 2025, Ventyx updated its Phase 2 trial of VTX2735 for &hellip; Continue reading \"INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-09T01:33:33+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2457789\/logo2_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm","datePublished":"2026-01-09T01:33:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/"},"wordCount":384,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2457789\/logo2_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/","name":"INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2457789\/logo2_Logo.jpg","datePublished":"2026-01-09T01:33:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2457789\/logo2_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2457789\/logo2_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/925743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=925743"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/925743\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=925743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=925743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=925743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}